News

Scientists report that antibodies made in response to a vaccine against one hemorrhagic fever virus—Junin—can successfully disarm one of its cousins, Machupo, for which there’s currently no vaccine.

Biologists report they have transferred a memory from one marine snail to another

Globally, cancer is the second leading cause of death, also because the efficiency of chemotherapeutics is inadequate due to poor delivery to the tumor. Prof. Olivia Merkel and her team develop targeted nanocarrier systems to increase the delivery rates of therapeutic formulations and their specific uptake into the target cells.

Based on the sugar structures on their surface, bacteria can be classified in subgroups. As a rule, an antibody eliminates only one subgroup and does not protect against other microbes. However, in studies with the bacterium Klebsiella pneumoniae, researchers have now been the first to find that the immune system also produces antibodies that recognize and neutralize various microorganisms.

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

A synthetic biology research team has combined cell-free protein synthesis and mass spectrometry to develop a new biotech technique that promises to accelerate research into protein therapies. The fruits of their labour could one day become the next defence against antibiotic-resistant supergerms or the next new drug.

The Food and Drug Administration has approved CAR T therapy products for adults with diffuse large B-cell lymphoma and pediatric and young adults suffering from acute lymphoblastic leukemia. Now, researchers at Moffitt Cancer Center are working to expand this revolutionary therapy to other cancers.

A new collaborative study has identified and studied Ebola antibodies that could be used to design universal therapeutics that are effective against many different Ebola species.

On April 26, 2018, the Girls’Day, intended to support schoolgirls with their professional orientation, took place again nationwide in Germany.

SYGNIS AG has announced the completion of the acquisition of TGR Biosciences, the Australian research reagents company.